secwatch.observer — SEC 8-K summary
======================================

Issuer:     PHIBRO ANIMAL HEALTH CORP (PAHC)
CIK:        0001069899
Form:       8-K
Filed at:   2024-02-07T23:59:59+00:00
Accession:  0001558370-24-000864
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Phibro reports Q2 diluted EPS of $0.03 on net income of $1.3M; reaffirms adjusted EBITDA guidance
--------------------------------------------------------------------------------

- Net sales $249.9M (+2% YoY); Animal Health segment up 6% led by 31% vaccine growth.
- GAAP net income $1.3M, diluted EPS $0.03, down from $7.2M and $0.18 a year ago.
- Adjusted EBITDA $29.5M (-5% YoY); adjusted diluted EPS $0.33 (-2%).
- FY2024 guidance: reaffirmed adjusted EBITDA $106-$112M; GAAP net income lowered to $12-$17M (down 55%).
- Includes $4.2M Brazil employment tax litigation charge and $7.5M foreign currency losses from Argentina devaluation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1069899/000155837024000864/0001558370-24-000864-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1069899/000155837024000864/pahc-20240207x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-000864

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer